Guggenheim Capital’s AIM ImmunoTech AIM Stock Holding History

Guggenheim Capital’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4	Closed	-$8K	–	2824
2018 Q1	$8K	Hold	4	–	–	﹤0.01%	2770
2017 Q4	$7K	Sell	4 -1	-20%	-$1.44K	﹤0.01%	2700
2017 Q3	$7K	Buy	5 +2	+67%	+$3.51K	﹤0.01%	2793
2017 Q2	$6K	Hold	3	–	–	﹤0.01%	2822
2017 Q1	$7K	Buy	+3	New	+$7.67K	﹤0.01%	2828
2016 Q3	–	Sell	-2	Closed	-$10K	–	3026
2016 Q2	$10K	Hold	2	–	–	﹤0.01%	2850
2016 Q1	$12K	Buy	+2	New	+$12.8K	﹤0.01%	2867
2015 Q4	–	Sell	-1	Closed	-$7K	–	3214
2015 Q3	$7K	Hold	1	–	–	﹤0.01%	2940
2015 Q2	$8K	Hold	1	–	–	﹤0.01%	3027
2015 Q1	$9K	Hold	1	–	–	﹤0.01%	3023
2014 Q4	$8K	Buy	+1	New	+$14.9K	﹤0.01%	2998
2014 Q3	–	Sell	-2	Closed	-$30.8K	–	2981
2014 Q2	$25K	Hold	2	–	–	﹤0.01%	3152
2014 Q1	$35K	Buy	2 +1	+100%	+$21.2K	﹤0.01%	3175
2013 Q4	$18K	Hold	1	–	–	﹤0.01%	3143
2013 Q3	$15K	Hold	1	–	–	﹤0.01%	3033
2013 Q2	$10K	Buy	+1	New	+$11.9K	﹤0.01%	3017

Other funds holding AIM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return

Guggenheim Capital's AIM Position: Q2 2018 in Review

Guggenheim Capital sold out of AIM ImmunoTech (AIM) in Q2 2018, closing a stake of 4 shares — an estimated $8K sold.

Guggenheim Capital first reported a position in AIM in Q2 2013 and held it in 16 quarters. The position peaked at $35K in Q1 2014. 13 funds tracked by Wall St. Rank hold AIM as of Q2 2018.

Guggenheim Capital reported no remaining AIM ImmunoTech position as of Q2 2018 after selling out during the quarter.
Guggenheim Capital sold 4 AIM ImmunoTech shares in Q2 2018, an estimated $8K.
Guggenheim Capital first reported a position in AIM ImmunoTech in Q2 2013 and held it in 16 quarters.
Guggenheim Capital's AIM ImmunoTech position peaked at $35K in Q1 2014.
13 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.